Maintenance olaparib rechallenge in patients with platinum-sensitive relapsed ovarian cancer previously treated with a PARP inhibitor (OReO/ENGOT-ov38): a phase IIIb trial

References

Page 1

	Year	Citations
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer Kathleen N. Moore, Nicoletta Colombo, Giovanni Scambia, New England Journal of Medicine	2018	2.7K
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer Mansoor R. Mirza, Bradley J. Monk, Jørn Herrstedt, New England Journal of Medicine	2016	2.4K
Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer Antonio González-Martı́n, Bhavana Pothuri, Ignace Vergote, New England Journal of Medicine	2019	2.1K
Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer Isabelle Ray‐Coquard, Patricia Pautier, Sandro Pignata, New England Journal of Medicine	2019	1.9K
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial Éric Pujade-Lauraine, Jonathan A. Ledermann, Frédèric Selle, The Lancet Oncology Brca1/2 MutationMedicineCancer ManagementGynecologyOlaparib Tablets	2017	1.8K
Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial Robert L. Coleman, Amit M. Oza, Domenica Lorusso, The Lancet Rucaparib Maintenance TreatmentMedicineRecurrent Ovarian CarcinomaGynecologyCancer Treatment	2017	1.7K
Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial Jonathan A. Ledermann, Philipp Harter, Charlie Gourley, The Lancet Oncology Olaparib Maintenance TherapySerous Ovarian CancerMedicineCancer ManagementGynecology	2014	1.4K
Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer Robert L. Coleman, Gini F. Fleming, Mark F. Brady, New England Journal of Medicine	2019	886
Overall Survival With Maintenance Olaparib at a 7-Year Follow-Up in Patients With Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1/GOG 3004 Trial Paul DiSilvestro, Susana Banerjee, Nicoletta Colombo, Journal of Clinical Oncology	2022	432
Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial Andrés Poveda, Anne Floquet, Jonathan A. Ledermann, The Lancet Oncology	2021	391

Page 1